Overwhelming evidence suggested that approximately 43.5% of patients with pancreatic cancer may belong to high c-Myc expression, and aberrant expression of PD-L1 predicted poor prognosis and promoted pancreatic cancer progression (Wang et al., 2020). This evidence concerns the gene MYC and familial pancreatic carcinoma.